Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

被引：0

作者：

Leleu, Xavier ^{[1
,2
]}

Beksac, Meral ^{[3
]}

Chou, Takaaki ^{[4
]}

Dimopoulos, Meletios ^{[5
]}

Yoon, Sung-Soo ^{[6
]}

Prince, Henry Miles ^{[7
]}

Pour, Ludek ^{[8
]}

Shelekhova, Tatiana ^{[9
]}

Chari, Ajai ^{[10
]}

Khurana, Monica ^{[11
]}

Obreja, Mihaela ^{[11
]}

Qi, Ming ^{[12
]}

Oriol, Albert ^{[13
]}

Siegel, David ^{[14
]}

机构：

[1] Chu, Poitiers, France

[2] Inserm 1402CIC, Poitiers, France

[3] Ankara Univ, Ankara, Turkey

[4] Niigata Canc Ctr Hpt, Niigata, Japan

[5] Natl & Kapodistrian Univ Athens, Sch Med, Hematol & Med Oncol, Dept Clin Therapeut,Sch Med, Athens, Greece

[6] Seoul Natl Univ, Seoul, South Korea

[7] Peter MacCallum Canc Inst, East Melbourne, Australia

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Clin Profess Pathol, Saratov, Russia

[10] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[11] Amgen Inc, Thousand Oaks, CA USA

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[14] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MM; multiple myeloma; carfilzomib; cross-study comparison; weekly dosing; KdD;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-040

引用

页码：S288 / S288

页数：1

共 41 条

[1] Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
Leleu, Xavier
Beksac, Meral
Chou, Takaaki
Dimopoulos, Meletios A.
Yoon, Sung-Soo
Prince, H. Miles
Pour, Ludek
Shelekhova, Tatiana
Chari, Ajai
Khurana, Monica
Obreja, Mihaela
Qi, Ming
Oriol, Albert
Siegel, David Samuel DiCapua
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Leleu, Xavier
Beksac, Meral
Chou, Takaaki
Dimopoulos, Meletios
Yoon, Sung-Soo
Prince, H. Miles
Pour, Ludek
Shelekhova, Tatiana
Chari, Ajai
Khurana, Monica
Zhang, Jianqi
Obreja, Mihaela
Qi, Ming
Oriol, Albert
Siegel, David
LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 358 - 367
[3] Once-weekly (70 mg/m2) versus twice weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
Moreau, Philippe
Stewart, A. Keith
Dimopoulos, Meletios A.
Siegel, David Samuel DiCapua
Facon, Thierry
Berenson, James R.
Raje, Noopur S.
Berdeja, Jesus G.
Orlowski, Robert Z.
Yang, Hui
Ma, Haijun
Karina Klippel, Zandra
Zahlten-Kumeli, Anita
Mezzi, Khalid
Iskander, Karim
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[4] Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
Moreau, Philippe
Stewart, Keith A.
Dimopoulos, Meletios
Siegel, David
Facon, Thierry
Berenson, James
Raje, Noopur
Berdeja, Jesus G.
Orlowski, Robert Z.
Yang, Hui
Ma, Haijun
Klippel, Zandra
Zahlten-Kumeli, Anita
Mezzi, Khalid
Iskander, Karim
Mateos, Maria-Victoria
CANCER MEDICINE, 2020, 9 (09): : 2989 - 2996
[5] Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Richez, Valentine
Gruchet, Cecile
Guidez, Stephanie
Fouquet, Guillemette
Azais, Isabelle
Durand, Geraldine
Javaugue, Vincent
Brigaud, Antoine
Plasse, Florent
Diolez, Jeremie
Machet, Antoine
Moya, Niels
Gardeney, Helene
Franques, Paul
Bobin, Arthur
Levy, Anthony
Sabirou, Florence
Bonnin, Anthony
Dieval, Celine
Primault, Sylvain
Barrier, Jocelyn
Fleck, Emmanuel
Bouyier, Sabrina
Daras, Claire
Princet, Isabelle
Bauwens, Delphine
Legros, Laurence
Fuzibet, Jean-Gabriel
Gil, Angela
Bridoux, Frank
Avet-Loiseau, Herve
Leleu, Xavier
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : E17 - E20
[6] Carfilzomib Weekly 20/56mg/m2, Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma
Valentine, Richez
Guidez, Stephanie
Azais, Isabelle
Durand, Geraldine
Javaugue, Vincent
Brigaud, Antoine
Plasse, Florent
Diolez, Jeremie
Machet, Antoine
Moya, Niels
Gruchet, Cecile
Bobin, Arthur
Levy, Anthony
Sabirou, Florence
Bonnin, Anthony
Dieval, Celine
Primault, Sylvain
Barrier, Jocelyn
Fleck, Emmanuel
Daras, Claire
Princet, Isabelle
Bauwens, Delphine
Fouquet, Guillemette
Bridoux, Frank
Loiseau, Herve Avet
Leleu, Xavier
BLOOD, 2017, 130
[7] Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Weisel, Katja
Nooka, Ajay K.
Terpos, Evangelos
Spencer, Andrew
Goldschmidt, Hartmut
Dirnberger, Franziska
DeCosta, Lucy
Yusuf, Akeem
Kumar, Shaji
LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1887 - 1896
[8] Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized ARROW study)
Moreau, Philippe
Kumar, Shaji
Boccia, Ralph
Iida, Shinsuke
Goldschmidt, Hartmut
Cocks, Kim
Trigg, Andrew
Zahlten-Kumeli, Anita
Yucel, Emre
Panjabi, Sumeet S.
Dimopoulos, Meletios
LEUKEMIA, 2019, 33 (12) : 2934 - 2946
[9] Carfilzomib weekly 20/56mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
Richez, Valentine
Guidez, Stephanie
Azais, Isabelle
Durand, Geraldine
Javaugue, Vincent
Brigaud, Antoine
Machet, Antoine
Moya, Niels
Gruchet, Cecile
Bobin, Arthur
Levy, Anthony
Sabirou, Florence
Dieval, Celine
Fleck, Emmanuel
Princet, Isabelle
Bauwens, Delphine
Fouquet, Guillemette
Bridoux, Frank
Avet-Loiseau, Herve
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Bortezomib: Once-Weekly 1.6mg/m2 Maybe a Better Choice Compared with Twice-Weekly 1.3mg/m2 in Newly Dignosed Multiple Myeloma
Li, Yubin
Li, Fangfang
Song, Wangshan
Zhan, Zhumei
Li, Xiangxin
Wang, Lingling
Li, Fanglin
Hou, Ming
Li, Hao
Wang, Luqun
BLOOD, 2019, 134

← 1 2 3 4 5 →